RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

Shaun Bagai, Chief Executive Officer of RenovoRx

“We generated record results in the third quarter as revenue exceeded the million-dollar threshold and we continued to deliver on all three of our core priorities”

Shaun Bagai, Chief Executive Officer of RenovoRx

“First, revenue increased four-fold year-over-year. Second, we ended the quarter with 26 active commercial cancer center customers, compared to 21 at the end of the second quarter 2026. Third, we are seeing physician-driven expansion of our TAMP(™ )platform, enabled by our FDA-cleared RenovoCath device, into applications beyond locally advanced pancreatic cancer, highlighting the potential for broader clinical adoption.”

Shaun Bagai, Chief Executive Officer of RenovoRx

“Driving much of our growth is our fully staffed sales team that continues to gain traction and accelerate customer engagement and adoption of TAMP.”

Shaun Bagai, Chief Executive Officer of RenovoRx

“The sales team, comprised of a Vice President of Sales and Market Development, and five Regional Market Development Managers, is strategically deployed to cover major U.S. cancer centers.”

Shaun Bagai, Chief Executive Officer of RenovoRx

“Our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors, such as pancreatic cancer.”

Shaun Bagai, Chief Executive Officer of RenovoRx

“Looking ahead, given the strong momentum, we continue to expect full-year 2026 revenue for RenovoCath in the range of $3.75 million to $4.25 million, which would more than triple 2025 revenue at the midpoint.”